News for OPGN Stock

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q OpGen Announced 1-for-10 Reverse Stock Split OpGen Provides Update on Business Operations and Strategic Opportunities OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K OpGen Announces Acquisition of Preferred Stock by David Lazar OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference OpGen Reports First Quarter 2023 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time OpGen Announces Closing of $3.5 Million Public Offering OpGen Announces Pricing of $3.5 Million Public Offering OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth OpGen Announces Exercise of All Prefunded Warrants OpGen subsidiary Ares Genetics announces granting of key patent in China OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project OpGen Announces Closing of $7.5 Million Public Offering OpGen Announces Pricing of $7.5 Million Public Offering OpGen Announced 1-for-20 Reverse Stock Split OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support OpGen Announces Closing of $3.38 Million Registered Direct Offering OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel OpGen Announces $3.38 Million Registered Direct Offering OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients OpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection Panel OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine OpGen Reports First Quarter 2022 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology OpGen Announces Successful Completion of Unyvero A30 Development Milestone OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022 OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents OpGen Announces Results of Special Meeting of Stockholders OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock OpGen Appoints Albert Weber as Chief Financial Officer OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time OpGen Subsidiary Ares Genetics Launches AREScloud OpGen Announces Closing of $15 Million Registered Direct Offering OpGen Announces $15 Million Registered Direct Offering OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021 OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program OpGen Announces Partial Adjournment of Annual Meeting OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AMR Gene Panel for Isolates Data Presented at World Microbe Forum OpGen Group Company Ares Genetics Presents R&D Pipeline Updates OpGen Announces Partial Adjournment of Annual Meeting for Proposal 2 with All Other Proposals Passed OpGen Group Company Ares Genetics Presents at AWS and Twist Bioscience Webinars OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland OpGen Reports First Quarter 2021 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients OpGen Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in COVID-19 Pneumonia Patients and Presents Data on Unyvero HPN Panel at ECCVID 2020 OpGen Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020 OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing OpGen, Inc. Announces $25 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update OpGen Subsidiary Curetis and Annar Enter into Unyvero Distribution Partnership for Colombia Results from 1,400 Patient Sample Multicenter Study Published: Unyvero LRT BAL Panel Provides Accurate Detection in Bronchoalveolar Lavage Fluid, Allowing Enhanced Diagnosis of Lower Respiratory Tract Infections OpGen Announces Planned Leadership Transition at Next Generation Sequencing and Bioinformatics Subsidiary Ares Genetics OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects Granting of Key Patent OpGen, Inc. Announces $10 Million Private Placement Priced at the Market OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Testing Service for Native Specimens and Receives Bulk Order from Public Health Agency OpGen Reports Third Quarter 2020 Financial Results and Provides Business Update OpGen to Provide Business Update and Financial Results for the Third Quarter 2020 OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators OpGen Provides Business and Pipeline Update and Announces Preliminary Unaudited Revenue and Cash Position for the Third Quarter 2020 OpGen Issues Formal Response to FDA’s Requests for Additional Information and Expects Near Term FDA Clearance Decision for Acuitas AMR Gene Panel OpGen Group Company Ares Genetics Wins Austrian Digitization Award for ares-genetics.cloud OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators OpGen Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in COVID-19 Pneumonia Patients and Presents Data on Unyvero HPN Panel at ECCVID 2020 OpGen, Inc. Announces Notice of Annual Meeting Venue Change Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing OpGen Group Company Ares Genetics Nominated for Austrian Innovation Award for AI-powered Molecular Antibiotic Susceptibility Test Key Publication of Clinical Study Demonstrates Unyvero Lower Respiratory Tract (LRT) Panel is Likely to Alter Antibiotic Management of Significant Numbers of Patients Presenting with Suspected Pneumonia OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19 OpGen Reports Second Quarter 2020 Financial Results and Provides Business Update OpGen Co-Markets COVID-19 Antibody Test Kit OpGen to Provide Business Update and Financial Results for the Second Quarter 2020 Menarini Silicon Biosystems Partners with OpGen to Broaden Distribution of CELLSEARCH Platform in North America OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours OpGen CEO and Chairman of the Board Issue Letters to Stockholders OpGen Subsidiary Curetis GmbH Secures Access to Additional EUR 5.0 Million Non-Dilutive Debt Financing Tranche from EIB OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections OpGen to Provide Business Update and Financial Results for the First Quarter 2020